Last Updated 13 December 2013
The prostate cancer market has witnessed considerable changes over the last three years, owing to the launch of five new therapies for treatment of metastatic castrate-resistant prostate cancer (mCRPC). Abiraterone (Johnson & Johnson/Janssen Biotech/Janssen-Cilag’s Zytiga), initially approved for mCRPC patients who have received prior treatment with docetaxel (Sanofi’s Taxotere, generics), is gaining widespread use in the commercially lucrative chemotherapy-naive setting, following its label extension in the United States and Europe. Enzalutamide (Medivation/Astellas Pharma’s Xtandi) launched in 2012 in the United States and 2013 in Europe, follows abiraterone and promises to compete fiercely for a share of the mCRPC market. The expected launch of several emerging therapies for prostate cancer over the next decade will heighten the competition, and it will be imperative for current and emerging therapies to differentiate and position themselves to maximize clinical and commercial success.
Questions Answered in This Report:
- We forecast healthy annual growth in the prostate cancer market over the ten-year forecast period (2012-2022). What factors are driving and constraining market growth? Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market?
- Emulating the development path of abiraterone, enzalutamide was first approved for docetaxel-pretreated mCRPC in the United States and Europe, and it is expected to gain a label extension for chemotherapy-naive mCRPC in the near-term. How do key opinion leaders expect enzalutamide to affect current medical practice? To what extent will the drug compete with abiraterone? Which therapies will pose the greatest threat to enzalutamide?
- Bone metastasis is a therapeutically relevant target in mCRPC; radium-223 (Bayer HealthCare/Algeta’s Xofigo) gained FDA approval in May 2013 and European approval in November 2013 for CRPC patients with symptomatic bone metastases. Which agents in development are targeting bone metastasis? How will they differentiate themselves from one another? Will they be clinically and commercially successful? How will these agents be positioned and fit into the treatment armamentarium for prostate cancer?
- Therapeutic vaccines will have a role in the mCRPC treatment through 2022. Which patient population will this class of agents be preferentially prescribed for? Will the emergence of novel hormonal agents impact patient share of therapeutic vaccines? What are thought leaders’ opinions of this class of agents?
- A majority of emerging therapies are focusing on initial approval in the CRPC settings; therefore, considerable opportunity remains for therapies to treat hormone-sensitive prostate cancer. What factors are shaping the hormone-sensitive market? Will current treatment practices change in this setting? What agents are in the late-stage pipeline for hormone-sensitive prostate cancer?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 30 country-specific interviews with thought leaders; physician surveys fielded to approximately 30 physicians (15 oncologists and 15 urologists) from each of the major markets.
Epidemiology: Diagnosed incidence of prostate cancer by risk for biochemical recurrence. Clinical and market relevant drug-treatable populations.
Population segments in market forecast: Newly diagnosed, low/intermediate risk (hormone-sensitive), newly diagnosed, high/very-high risk (hormone-sensitive), newly diagnosed, metastatic (hormone-sensitive), biochemically recurrent (hormone-sensitive), nonmetastatic castrate-resistant, first-line metastatic castrate-resistant, second-line castrate-resistant, and third- and fourth-line castrate-resistant.
Emerging therapies: Phase II: 28 drugs; Phase III: 8.
Michael Hughes, M.Sc., Ph.D.